Showing 301 - 320 results of 324 for search '(( significantly ((we decrease) OR (mean decrease)) ) OR ( significant increase decrease ))~', query time: 0.60s Refine Results
  1. 301

    Table 1_The knowledge paradox: an inverted U-shaped association between HIV knowledge and stigma among older men in Sichuan Province, Southwest China.docx by Zhihua Ye (3133311)

    Published 2025
    “…Regression analysis revealed an inverted U-shaped association. Stigma initially increased with increasing knowledge (linear β = 1.71, p < 0.001), peaked at a knowledge score of 4.14, and subsequently decreased with increasing knowledge gain (quadratic β = −0.21, p < 0.001). …”
  2. 302

    Data Sheet 1_Associations between obesity and arterial stiffness assessed by cardio-ankle vascular index in healthy children and adolescents.docx by Yuko Horikoshi (12202859)

    Published 2025
    “…</p>Methods<p>This was a cross-sectional study conducted in 2024. We evaluated CAVI and its associated factors in 590 children aged 6–15 years (mean age: 10.5 years, 51.0% female). …”
  3. 303

    Study group background characteristics. by Zicheng Hu (3825313)

    Published 2024
    “…In the untreated individuals (not including the <b><i>elites</i></b>) there was a steady increase in blood HIV-1 RNA through the full range of CD4+ T-cell loss that reached its highest mean levels in the <b><i>HAD</i></b> group. …”
  4. 304

    Table 1_Unveiling the global impact of hypertensive heart disease among individuals aged ≥ 65 years: metabolic risk factors and future projections for 2050.xlsx by Ning An (618997)

    Published 2025
    “…Join-point analysis revealed an increasing trend in age-standardized prevalence rates between 1990 and 2021, while mortality and DALYs rates decreased. …”
  5. 305

    Table 4_Unveiling the global impact of hypertensive heart disease among individuals aged ≥ 65 years: metabolic risk factors and future projections for 2050.xlsx by Ning An (618997)

    Published 2025
    “…Join-point analysis revealed an increasing trend in age-standardized prevalence rates between 1990 and 2021, while mortality and DALYs rates decreased. …”
  6. 306

    Image 1_Unveiling the global impact of hypertensive heart disease among individuals aged ≥ 65 years: metabolic risk factors and future projections for 2050.tif by Ning An (618997)

    Published 2025
    “…Join-point analysis revealed an increasing trend in age-standardized prevalence rates between 1990 and 2021, while mortality and DALYs rates decreased. …”
  7. 307

    Table 3_Unveiling the global impact of hypertensive heart disease among individuals aged ≥ 65 years: metabolic risk factors and future projections for 2050.xlsx by Ning An (618997)

    Published 2025
    “…Join-point analysis revealed an increasing trend in age-standardized prevalence rates between 1990 and 2021, while mortality and DALYs rates decreased. …”
  8. 308

    Table 2_Unveiling the global impact of hypertensive heart disease among individuals aged ≥ 65 years: metabolic risk factors and future projections for 2050.xlsx by Ning An (618997)

    Published 2025
    “…Join-point analysis revealed an increasing trend in age-standardized prevalence rates between 1990 and 2021, while mortality and DALYs rates decreased. …”
  9. 309

    Table 1_Eculizumab for the acute attack of neuromyelitis optica spectrum disorder.docx by Qingqing Zhuang (22109089)

    Published 2025
    “…Among LETM patients, one regained substantial lower limb strength (MRC grade 0 to 3 proximally, 4 distally), while the other showed improvement in distal strength (MRC grade 0 to 3). Serum sGFAP decreased from 278.0 to 130 pg/mL (p = 0.027), while sNfL levels transiently increased before stabilizing. …”
  10. 310

    Table6_Use of non-specific immunoglobulins in Catalonia in three third-level hospitals: a descriptive analysis of a hospital-prescribed medication registry.docx by J. Riera-Arnau (20431328)

    Published 2024
    “…In the sensitivity analysis, the A-level usage rate decreased to one-third and the B-level usage rate increased by 2–3 times. …”
  11. 311

    Table4_Use of non-specific immunoglobulins in Catalonia in three third-level hospitals: a descriptive analysis of a hospital-prescribed medication registry.docx by J. Riera-Arnau (20431328)

    Published 2024
    “…In the sensitivity analysis, the A-level usage rate decreased to one-third and the B-level usage rate increased by 2–3 times. …”
  12. 312

    Table2_Use of non-specific immunoglobulins in Catalonia in three third-level hospitals: a descriptive analysis of a hospital-prescribed medication registry.docx by J. Riera-Arnau (20431328)

    Published 2024
    “…In the sensitivity analysis, the A-level usage rate decreased to one-third and the B-level usage rate increased by 2–3 times. …”
  13. 313

    Table8_Use of non-specific immunoglobulins in Catalonia in three third-level hospitals: a descriptive analysis of a hospital-prescribed medication registry.docx by J. Riera-Arnau (20431328)

    Published 2024
    “…In the sensitivity analysis, the A-level usage rate decreased to one-third and the B-level usage rate increased by 2–3 times. …”
  14. 314

    Table5_Use of non-specific immunoglobulins in Catalonia in three third-level hospitals: a descriptive analysis of a hospital-prescribed medication registry.docx by J. Riera-Arnau (20431328)

    Published 2024
    “…In the sensitivity analysis, the A-level usage rate decreased to one-third and the B-level usage rate increased by 2–3 times. …”
  15. 315

    Table3_Use of non-specific immunoglobulins in Catalonia in three third-level hospitals: a descriptive analysis of a hospital-prescribed medication registry.docx by J. Riera-Arnau (20431328)

    Published 2024
    “…In the sensitivity analysis, the A-level usage rate decreased to one-third and the B-level usage rate increased by 2–3 times. …”
  16. 316

    Table7_Use of non-specific immunoglobulins in Catalonia in three third-level hospitals: a descriptive analysis of a hospital-prescribed medication registry.docx by J. Riera-Arnau (20431328)

    Published 2024
    “…In the sensitivity analysis, the A-level usage rate decreased to one-third and the B-level usage rate increased by 2–3 times. …”
  17. 317

    Table1_Use of non-specific immunoglobulins in Catalonia in three third-level hospitals: a descriptive analysis of a hospital-prescribed medication registry.DOCX by J. Riera-Arnau (20431328)

    Published 2024
    “…In the sensitivity analysis, the A-level usage rate decreased to one-third and the B-level usage rate increased by 2–3 times. …”
  18. 318

    Supplementary Material for: Efficacy of penetrating canaloplasty versus trabeculectomy in patients with bilateral primary glaucoma: a self-control study by figshare admin karger (2628495)

    Published 2025
    “…Complete (without medication) and qualified success (with/without medication) were defined as IOP ≤21 mmHg and ≥20% IOP reduction. Results: Mean IOP decreased from 32.5±8.87mmHg on 2.3±1.43 medications at baseline to 14.6±4.41mmHg on 0.20±0.58 medications at 12 months in TRAB group (both p<0.0001) and from 30.0±9.61mmHg on 2.7±1.10 medications to 14.8±4.63mmHg on 0.12±0.44 medications in PCP group (both p<0.0001). …”
  19. 319

    Data Sheet 1_A multimodal approach for establishing ACTL6A and ERCC1 as chemoresistance genes in locally advanced head and neck cancer.docx by Raushan Kumar Chaudhary (15664043)

    Published 2025
    “…</p>Results<p>A total of 77 LAHNC patients were enrolled in this study, of which 96.1% were men and 3.9% were women with a mean age of 52.88 ± 9.68 years. The median expressions of ERCC1 were significantly increased (p < 0.001) after 50% (0.19) and 100% CRT (0.23) compared to the baseline value (0.14), whereas ACTL6A expression decreased from 4.77 to 3.87 after 50% CRT (p < 0.05) and increased to 5.43 after 100% CRT. …”
  20. 320

    <i>mig-21</i> sensitizes adult DTCs to polarizing signals. by Xin Li (51274)

    Published 2025
    “…However, migration cessation is not rescued; a significant increase in “overmigration” defects is observed between marked control (n=4/57) and <i>mig-21(u787)</i> on <i>vab-3</i> RNAi (n=17/65), p < 0.05. …”